List view / Grid view



Positive topline results from two Phase III dupilumab studies

1 April 2016 | By Victoria White

Sanofi and Regeneron have announced positive topline results from two placebo-controlled Phase III studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis (AD).

Send this to a friend